Dublin, Feb. 19, 2020 (GLOBE NEWSWIRE) -- The "Primary Ciliary Dyskinesia (PCD) - Pipeline Insight, 2020" drug pipelines has been added to ResearchAndMarkets.com's offering.
Primary Ciliary Dyskinesia (PCD) Pipeline Insight, 2020 outlays comprehensive insights of present clinical development scenario and growth prospects across the Primary Ciliary Dyskinesia (PCD) market.
A detailed picture of the Primary Ciliary Dyskinesia (PCD) pipeline landscape is provided, which includes the disease overview and Primary Ciliary Dyskinesia (PCD) treatment guidelines. The assessment part of the report embraces in-depth Primary Ciliary Dyskinesia (PCD) commercial assessment and clinical assessment of the Primary Ciliary Dyskinesia (PCD) pipeline products from the pre-clinical developmental phase to the marketed phase.
In the report, a detailed description of the drug is proffered including mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Primary Ciliary Dyskinesia (PCD) collaborations, licensing, mergers and acquisition, funding, designations, and other product-related details.
The report provides insights into:
Scope of the Report
Key Topics Covered
1. Report Introduction
2. Primary Ciliary Dyskinesia (PCD)
2.1. Overview
2.2. History
2.3. Primary Ciliary Dyskinesia (PCD) Symptoms
2.4. Causes
2.5.Pathophysiology
2.6. Primary Ciliary Dyskinesia (PCD) Diagnosis
2.6.1. Diagnostic Guidelines
3. Primary Ciliary Dyskinesia (PCD) Current Treatment Patterns
3.1. Primary Ciliary Dyskinesia (PCD) Treatment Guidelines
4. Primary Ciliary Dyskinesia (PCD) - Analytical Perspective
4.1. In-depth Commercial Assessment
4.1.1. Primary Ciliary Dyskinesia (PCD) companies collaborations, Licensing, Acquisition - Deal Value Trends
4.1.1.1. Assessment Summary
4.1.2. Primary Ciliary Dyskinesia (PCD) Collaboration Deals
4.1.2.1. Company-Company Collaborations (Licensing / Partnering) Analysis
4.1.2.2. Company-University Collaborations (Licensing / Partnering) Analysis
4.1.2.3. Primary Ciliary Dyskinesia (PCD) Acquisition Analysis
5. Therapeutic Assessment
5.1. Clinical Assessment of Pipeline Drugs
5.1.1. Assessment by Phase of Development
5.1.2. Assessment by Product Type (Mono / Combination)
5.1.2.1. Assessment by Stage and Product Type
5.1.3. Assessment by Route of Administration
5.1.3.1. Assessment by Stage and Route of Administration
5.1.4. Assessment by Molecule Type
5.1.4.1. Assessment by Stage and Molecule Type
5.1.5. Assessment by MOA
5.1.5.1. Assessment by Stage and MOA
5.1.6. Assessment by Target
5.1.6.1. Assessment by Stage and Target
6. Primary Ciliary Dyskinesia (PCD) Late Stage Products (Phase-III)
7. Primary Ciliary Dyskinesia (PCD) Mid Stage Products (Phase-II)
8. Early Stage Products (Phase-I)
9. Pre-clinical Products and Discovery Stage Products
10. Inactive Products
11. Dormant Products
12. Primary Ciliary Dyskinesia (PCD) Discontinued Products
13. Primary Ciliary Dyskinesia (PCD) Product Profiles
13.1. Drug Name: Company
13.1.1. Product Description
13.1.1.1. Product Overview
13.1.1.2. Mechanism of action
13.1.2. Research and Development
13.1.2.1. Clinical Studies
13.1.3. Product Development Activities
13.1.3.1. Collaboration
13.1.3.2. Agreements
13.1.3.3. Acquisition
13.1.3.4. Patent Detail
13.1.4. Tabulated Product Summary
13.1.4.1. General Description Table
14. Primary Ciliary Dyskinesia (PCD) Key Companies
15. Primary Ciliary Dyskinesia (PCD) Key Products
16. Dormant and Discontinued Products
16.1. Dormant Products
16.1.1. Reasons for being Dormant
16.2. Discontinued Products
16.2.1. Reasons for the Discontinuation
17. Primary Ciliary Dyskinesia (PCD) Unmet Needs
18. Primary Ciliary Dyskinesia (PCD) Future Perspectives
19. Primary Ciliary Dyskinesia (PCD) Analyst Review
Companies Mentioned
For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/e4n0yu
Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.
CONTACT: CONTACT: ResearchAndMarkets.com Laura Wood, Senior Press Manager press@researchandmarkets.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900